Clinical endpoint adjudication

In pivotal clinical effectiveness trials, the primary endpoint needs to be precisely defined and quantified because any misclassification could introduce noise and possible bias, potentially leading to incorrect trial conclusions. This misclassification is commonly addressed by having an independent clinical endpoint adjudication committee where all relevant clinical information is provided and a panel of clinical experts categorises the primary endpoint, blind to treatment allocation. This strategy has been established as a basic cornerstone of modern robust trial methodology. However, does this apparently rigorous approach truly deliver more robust clinical findings?